Development of Optimized Tissue Factor-Targeted Peptide Amphiphile Nanofibers to Slow Non-Compressible Torso Hemorrhage

• Published in: ACS nano Vol. 14; no. 6; pp. 6649 - 6662
• Main Authors: Klein, Mia K., Kassam, Hussein Aziz, Lee, Robert H., Bergmeier, Wolfgang, Peters, Erica B., Gillis, David C., Dandurand, Brooke R., Rouan, Jessica R., Karver, Mark R., Struble, Mark D., Clemons, Tristan D., Palmer, Liam C., Gavitt, Brian, Pritts, Timothy A., Tsihlis, Nick D., Stupp, Samuel I., Kibbe, Melina R.
• Format: Journal Article
• Language: English
• Published: 03.06.2020
• ISSN: 1936-0851; 1936-086X
• DOI: 10.1021/acsnano.9b09243

Non-compressible torso hemorrhage accounts for a significant portion of preventable trauma deaths. We report here on the development of injectable, targeted supramolecular nanotherapeutics based on peptide amphiphile (PA) molecules that are designed to target tissue factor (TF) and, therefore, selectively localize to sites of injury to slow hemorrhage. Eight TF-targeting sequences were identified, synthesized into PA molecules, co-assembled with non-targeted backbone PA at various weight percentages, and characterized via circular dichroism spectroscopy, transmission electron microscopy, and X-ray scattering. Following intravenous injection in a rat liver hemorrhage model, two of these PA nanofiber co-assemblies exhibited the most specific localization to the site of injury compared to controls (p<0.05), as quantified using immunofluorescence imaging of injured liver and uninjured organs. To determine if the nanofibers were targeting to TF in vivo , a mouse saphenous vein laser injury model was performed and showed that TF-targeted nanofibers co-localized with fibrin, demonstrating increased levels of nanofiber at TF-rich sites. Thromboelastograms obtained using samples of heparinized rat whole blood containing TF demonstrated that no clots were formed in the absence of TF-targeted nanofibers. Lastly, both PA nanofiber co-assemblies decreased blood loss in comparison to sham and backbone nanofiber controls by 35% to 59% (p<0.05). These data demonstrate an optimal TF-targeted nanofiber that localizes selectively to sites of injury and TF exposure, and, interestingly, reduces blood loss. This research represents a promising initial phase in the development of a TF-targeted injectable therapeutic to reduce preventable deaths from hemorrhage.